Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott's LO Loestrin FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) has received approval from the US Food and Drug Administration (FDA) for the prevention of pregnancy.
Subscribe to our email newsletter
Warner Chilcott claimed that LO Loestrin FE offers women the lowest dosage of estrogen (10mcg) of any oral contraceptive currently available in the US market.
LO Loestrin FE is expected to be launched by Warner Chilcott in early 2011.
Warner Chilcott president and CEO Roger Boissonneault said that they were excited about the approval of LO Loestrin FE, which complements their women’s healthcare franchise and expands the product offerings in their branded oral contraceptive portfolio.
Warner Chilcott is a specialty pharmaceutical company currently focused on the gastroenterology, women’s healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.